Raltitrexed induces mitochondrial‑mediated apoptosis in SGC7901 human gastric cancer cells

Song Xue1, Ying-Xia Chen1, Shu-Kui Qin1

  • 1Department of Medical Oncology, 81 Hospital of PLA, 81 Clinical College, Anhui Medical University, Nanjing, Jiangsu 210002, P.R. China.

Insights

Raltitrexed effectively inhibits gastric cancer cell growth by inducing apoptosis via the mitochondrial pathway. This mechanism involves caspase-3 activation and upregulation of thymidylate synthase (TS) expression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Raltitrexed is a thymidylate synthase (TS) inhibitor investigated for advanced gastric cancer.
  • Understanding raltitrexed's apoptosis mechanisms in gastric cancer cells is crucial for therapeutic development.

Purpose of the Study:

  • To investigate the apoptosis mechanisms of raltitrexed in SGC7901 human gastric cancer cells.
  • To elucidate the role of the mitochondrial signaling pathway and caspase-3 activation in raltitrexed-induced cell death.

Main Methods:

  • Cell counting kit-8 (CCK-8) assay for cytotoxicity.
  • Hoechst 33258 staining and flow cytometry for apoptosis, cell cycle, mitochondrial potential, and ROS.
  • Caspase-3 activity assay, Western blot, and quantitative PCR for molecular analysis.

Main Results:

  • Raltitrexed inhibited SGC7901 cell growth dose- and time-dependently.
  • Apoptosis was induced, evidenced by morphological changes, G0/G1 cell cycle arrest, reduced mitochondrial potential, and increased ROS.
  • Raltitrexed activated caspase-3, increased Bax, cytochrome c, and cleaved caspase-3, decreased Bcl-2, and upregulated TS protein and mRNA.

Conclusions:

  • Raltitrexed induces apoptosis in SGC7901 cells through a caspase-3-dependent mitochondrial pathway.
  • Raltitrexed upregulates thymidylate synthase (TS) protein and mRNA expression.
  • These findings support raltitrexed's potential as a chemotherapeutic agent for gastric cancer.